SINCE 2010
1. Kim W-Y, Kim MJ, Moon HJ, Kin J-S, Woo JK, Zhang G, Feng L, Van Pelt C, Lee JJ, Glisson B, Lippman S, Wistuba I, Hong WK, and Lee HY Behrens C, Prudkin L, Miller Y, Lee J, Wistuba II, Hong WK, Lee HY. Dual Impact of insulin-like growth factor (IGF)-binding protein 3 on IGF action and lung cancer development. Endocrinology Jun;152(6):2164-73. 2011.
2. Kim W-Y, Jin Q, Frudkin L, Kin J-S, Morgilo F, Feng L, Kim ES, Hennessy B, Lee JS, Mills G, Lee JJ, Glisson B, Lippman S, Wistuba I, Hong WK, and Lee HY EGFR and K-Ras Mutations and Resistance of Lung Cancer to the IGF-1R Tyrosine kinase Inhibitors, Cancer, (ACS) 15;118(16):3993-4003 2012
3. Kim WY. NeuroD1 is an upstream regulator of NSCL1. Biochem Biophys Res Commun. 2;419(1):27-31. 2012
4. Oh SH*, Kim WY*, Lee OH*, Kang JH, Woo JK, Kim JH, Glisson B, Lee HY. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma. Cancer Sci. doi: 10.1111/j.1349-7006.2012.02301. 2012 (*, Co-First Authors)
5. Kim WY. NeuroD regulates neuronal migration. Mol Cells. May;35(5):444-9 2013
6. Lee E, Han S, Jin GH, Lee HJ, Kim WY, Ryu JH, Jeon R. Synthesis and anticancer activity of aminodihydroquinoline analogs: identification of novel proapoptotic agents. Bioorg Med Chem Lett. Jul 1;23(13):3976-8 2013.
7. Kim HI, Song Y, Kim WY, Lee JE. Association of adherence to the seventh report of the Joint National Committee guidelines with hypertension in Korean men and women. Nutr Res. 33(10):789-95 2013.
8. Li H, Lee HJ, Ahn YH, Kwon HJ, Jang CY, Kim WY, Ryu JH Tussilagone suppresses colon cancer cell proliferation by promoting the degradation of β-catenin. Biochem Biophys Res Commun. 443(1):132-7 2014.
9. Kim YK, Kim S, Shin YJ, Hur YS, Kim WY, Lee MS, Cheon CI, Verma DP. Ribosomal protein S6, a target of rapamycin, is involved in the regulation of rRNA genes by possible epigenetic changes in Arabidopsis. J Biol Chem. 289(7):3901-12 2014.
10. Jung Y, Park H, Zhao HY, Jeon R, Ryu JH, Kim WY. Systemic Approaches Identify a Garlic-Derived Chemical, Z-ajoene, as a Glioblastoma Multiforme Cancer Stem Cell-Specific Targeting Agent. Mol Cells. 37(7):547-53 2014.
11. Jin Q, Lee HJ, Min HY, Smith JK, Hwang SJ, Whang YM, Kim WY, Kim YH, Lee HY. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3. Carcinogenesis. 35(10):2232-43 2014.
12. Shin DH, Xuan S, Kim WY, Bae GU and Kim JS. CD133 antibody-conjugated immunoliposomes encapsulating gemcitabine for targeting glioblastoma stem cells J. Mater. Chem. B, 2, 3771-3781 2014
13. Shin DH, Kim WY, Kim JS. Enhanced Anticancer Effect of Liposome Encapsulated Choline Kinase-siRNA in Mice (vol 22, pg 344, 2014)
14. Jung Y, Kim WY. Cancer stem cell targeting: Are we there yet? Arch Pharm Res. 2015 Mar;38(3):414-422. 2015
15. Hur YS, Um JH, Kim S, Kim K, Park HJ, Lim JS, Kim WY, Jun SE, Yoon EK, Lim J, Ohme-Takagi M, Kim D, Park J, Kim GT, Cheon CI. Arabidopsis thaliana homeobox 12 (ATHB12), a homeodomain-leucine zipper protein, regulates leaf growth by promoting cell expansion and endoreduplication. New Phytol. 2015 Jan;205(1):316-328 2015
16. Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. Cancer Lett. 2015 Jun 1;361(2):197-206 2015
17. Son O, Kim S, Shin YJ, Kim WY, Koh HJ, Cheon CI. Identification of nucleosome assembly protein 1 (NAP1) as an interacting partner of plant ribosomal protein S6 (RPS6) and a positive regulator of rDNA transcription. Biochem Biophys Res Commun. 2015 Sep 18;465(2):200-5.
18. Jung YC, Han S, Hua L, Ahn YH, Cho H, Lee CJ, Lee H, Cho YY, Ryu JH, Jeon R, Kim WY. Kazinol-E is a specific inhibitor of ERK that suppresses the enrichment of a breast cancer stem-like cell population. Biochem Biophys Res Commun. 2016 Feb 5;470(2):294-9..
19. Han S, Woo JK, Jung Y, Jeong D, Kang M, Yoo YJ, Lee H, Oh SH, Ryu JH, Kim WY. Evodiamine selectively targets cancer stem-like cells through the p53-p21-Rb pathway. Biochem Biophys Res Commun. 2016 Jan 22;469(4):1153-8
20. An Y, Lee E, Yu Y, Yun J, Lee MY, Kang JS, Kim WY, Jeon R. Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors Bioorg Med Chem Lett. 2016 Jul 1;26(13):3067-72
21. Kim N, Yim HY, He N, Lee CJ, Kim JH, Choi JS, Lee HS, Kim S, Jeong E, Song M, Jeon SM, Kim WY, Mills GB, Cho YY, Yoon S. Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Sci Rep. 2016 Jul 19;6:29721.
22. Lee, H, Kim Y*, Ryu JH, Kim, WY* ATM/CHK/p53 pathway dependent chemopreventive and therapeutic activity on lung cancer by pterostilbene, Plos One 2016 Sep 9;11(9):e0162335. (*, Co-Corresponding)
23. Song M, Lee H, Nam MH, Jeong E, Kim S, Hong Y, Kim N, Yim HY, Yoo YJ, Kim JS, Kim JS, Cho YY, Mills G, Kim, WY *, Yoon S*. Loss-of-function screens of druggable targetome against cancer stem-like cells.. FASEB Journal 2017 Feb;31(2):625-635 (*, Co-Corresponding) 5yr IF 5.4, 8% in Biology
24. Kim KW, Lee SJ, Kim WY, Seo JH, Lee HY. How Can We Treat Cancer Disease Not Cancer Cells? Cancer Res Treat. 2017 Jan 49
25. Park H, Yu Y, Kim H, Lee E, Lee H, Jeon R, Kim WY. Selective Targeting of Cancer Stem Cells by 2-Aminodihydroquinoline Analogs. Chem Pharm Bull (Tokyo). 2017 Apr 1;65(4):349-355
26. Won JY, Jang WY, Lee HR, Park SY, Kim WY, Park JH, Kim Y, Cho TH. Novel missense loss-of-function mutations of WNT1 in an autosomal recessive Osteogenesis imperfecta patient. Eur J Med Genet. 2017 May 17. (60): 411-415
27. Lee H, Kim N, Yoo YJ, Kim H, Jeong E, Choi S, Moon SU, Oh SH, Mills GB, Yoon S*, Kim WY*. β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer Oncogene. 2018 Oct (37) 5466-5475
28. Kim WY, Therapeutic targeting of lipid synthesis metabolism for selective elimination of cancer stem cells, Arch Pharm Res. 2019 42(1)
29. Hur YS, Kim J, Kim S, Son O, Kim WY, Kim GT, Ohme-Takagi M, Cheon CI dentification of TCP13 as an Upstream Regulator of ATHB12 during Leaf Development. Genes (Basel). 2019 Aug 26;10(9).
30. Jeong E, Park C, Moon SU, Cho J, Song M, Ryoo S, Gu H, Lee Y, Kim WY, Yoon S Dissecting phenotypic responses of the druggable targetome in cancers. Sci Rep. 2019 Aug 29;9(1):12513.
31. Choi S, Yoo YJ, Kim H, Lee H, Chung H, Nam MH, Moon JY, Lee HS, Yoon S, Kim WY. Clinical and biochemical relevance of monounsaturated fatty acid metabolism targeting strategy for cancer stem cell elimination in colon cancer. Biochem Biophys Res Commun. 2019 Oct 29;519(1):100-105.
32. Kim H, Yu Y, Choi S, Lee H, Yu J, Lee JH, Kim WY. Evodiamine Eliminates Colon Cancer Stem Cells via Suppressing Notch and Wnt Signaling Molecules. 2019 Dec 10;24(24). pii: E4520.
33. Hwang KT, Kim BH, Oh S, Park SY, Jung J, Kim J, Choi IS, Jeon SY, Kim WY. Prognostic Role of KRAS mRNA Expression in Breast Cancer. . J Breast Cancer. 2019 Dec 22(4):548-561
34. Lee CJ, An HJ, Kim SM, Yoo SM, Park J, Lee GE, Kim WY, Kim DJ, Kang HC, Lee JY, Lee HS, Cho S, Cho YY. FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation. Proc Natl Acad Sci U S A. 2020 Jan 117(1):584-594
35. Go GY, Jo A, Dong, Seo DW , Kim WY, Kim YK, So EY, Chen Q, Kang JS, Bae GU, Lee SJ. Ginsenoside Rb1 and Rb2 upregulate Akt/mTOR signaling-mediated muscular hypertrophy and myoblast differentiation J Ginseng Res 2020 May;44(3):435-441. doi: 10.1016/j.jgr.2019.01.007
36. Yu Y, Kim H, Choi S, Yu J, Lee JY, Lee H, Yoon S, Kim WY. Targeting a Lipid Desaturation Enzyme, SCD1, Selectively Eliminates Colon Cancer Stem Cells through the Suppression of Wnt and NOTCH Signaling. Cells. 2021 Jan 8;10(1):E106. doi: 10.3390/cells10010106.
37. Park M, Hwang JW, Cho Y, Kim S, Han SH, Yu J, Ha S, Kim WY, Kim SN, Kim IS, Kim YK. A novel synthetic microtubule inhibitor exerts antiproliferative effects in multidrug resistant cancer cells and cancer stem cells. Sci Rep. 2021 May 24;11(1):10822.
38. Pham HT, Lee KH, Jeong E, Woo S, Yu J, Kim WY, Lim YW, Kim KH, Kang KB. Species Prioritization Based on Spectral Dissimilarity: A Case Study of Polyporoid Fungal Species. J Nat Prod. 2021 Feb 26;84(2):298-309.
39. Kim Y, Lee J, Jeong S, Kim WY, Jeong E, Yoon S. Screening of the siGPCR library in combination with cisplatin against lung cancers. Sci Rep. 2022 Oct 17;12(1):17358.
40. Lee H, Choi SG, Ha S, Yoon S, Kim WY. ARL2 is required for homologous recombination repair and colon cancer stem cell survival. FEBS Open Bio. 2022 Aug;12(8):1523-1533.
41. Boo HJ, Min HY, Park CS, Park JS, Jeong JY, Lee SY, Kim WY, Lee JW, Oh SR, RW Park, Lee HY. Dual impact of IGF2 on alveolar stem cell function during tobacco-induced injury repair and development of pulmonary emphysema and cancer. Cancer Res. 2023 Jun 2;83(11):1782-1799. doi: 10.1158/0008-5472.CAN-22-3543.
42. Lee H, Ha S, Choi SG. Do SM, Yoon S, Kim YK, Kim WY. Oncogenic Impact of TONSL, a Homologous Recombination Repair Protein at the Replication Fork, in Cancer Stem Cells. Int J Mol Sci. 2023 May 31;24(11):9530. doi: 10.3390/ijms24119530
43. Choi SG, Bae HG, Jo DG, Kim WY. The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer. Genes (Basel). 2024 Jul 22;15(7):959. doi: 10.3390/genes15070959.
44. Choi SG, Shin M, Kim WY. Targeting the DNA damage response (DDR) of cancer cells with natural compounds derived from Panax ginseng and other plants. .Journal of Ginseng Research. 2025 Jan 1 ;49(1):XXX-XXX (in press)
Before 2011
1. Hong Y-S, Lee S-J, , Kim W-Y, Kim K-W. BAL31 Deletion analysis of the upstream sequences of the yeast ASP3 gene. Korean Biochemical J 25:739-744, 1992.
2. Kim W-Y, Yoo D-Y, Lee K-K, Park B-C, Kim K-W. Differential transcription of laminin subunits in mouse oocyte, preimplantation embryo and parthenogenote. Molecules and Cells 5:618-622, 1995.
3. Lee S-J, Lee J-H, Hong Y-S, , Kim W-Y, Chung K-S, Kim K-W. Transcriptional Regulatory Mechanism of the Yeast ASP3gene under Nitrogen Catabolite Repression. Molecules and Cells 5:651-657, 1995.
4. Kanno T, Kanno Y, Chen LF, Ogawa E, , Kim W-Y, Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol 18:2444-54, 1998.
5. Ahn MY, Huang G, Bae SC, Wee HJ, , Kim W-Y, Ito Y. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO(MTG8). Proc Natl Acad Sci U S A 95:1812-7, 1998.
6. Nagata T, Gupta V, Sorce D, , Kim W-Y, Sali A, Chait BT, Shigesada K, Ito Y, Werner MH. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nature Struct Biol 6:615-9, 1999.
7. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, , Kim W-Y, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C alpha promoter. J Biol Chem 274:31577-82, 1999.
8. Goger M, Gupta V, Kim W-Y, Shigesada K, Ito Y, Werner MH. Molecular insights into PEBP2/CBF beta-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBF beta. Nature Struct Biol 6:615-9, 1999
9. Kim W-Y, Sieweke S, Ogawa E, Wee H-J, Englmeier E, Graf T, Ito Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 18:1609-1620, 1999.
10. Ogihara H, Kanno T, Morii E, Kim DK, Lee YM, Sato M, , Kim W-Y, Nomura S, Ito Y, Kitamura Y. Synergy of PEBP2/CBF with mi transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene. Oncogene 18:4632-9, 1999.
11. Kim W-Y*, Fritzsch B*, Serls A, Bakel LA, Huang EJ, Reichardt LF, Barth DS, Lee JE. NeuroD-null mice are deaf due to a severe loss of the inner ear sensory neurons during development. Development 128:417-26, 2001.
12. Lee H-Y, Oh SH, Woo JK, , Kim W-Y, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, Hong WK. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97:1695-9, 2005.
13. Oh SH, Kim W-Y, Woo J-K, KIM J-H, Younes MN, Myers JN, Hong WK, Lee H-Y. Identification of insulin-like growth factor binding protein-3 as a farnesyltransferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clinical Cancer Res 12:653-61, 2006.
14. Morgillo F, Kim W-Y, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the IGF-1R pathway in the resistance of the NSCLC cells to treatment with gefitinib. Clin Cancer Res 13:2795-2803, 2007.
15. Oh SH, Woo JK, Yazici Y, Myers J, Kim W-Y, Park HJ, Suh YG, Kim KW, Park HJ, Suh YG, Kim KY, Hong WK, Lee,HY. Structural basis for depletion of heat shock protein 90 client proteins by the natural antitumor agent deguelin. J Natl Cancer Inst 99(12):949-61, 2007.
16. Kim W-Y, Shen J. Presenilins are required for maintenance of neural stem cells in the developing brain. Molecular Neurodegeneration (3) 2. 2008.
17. Cascone T, Morelli MP, Morgillo F, Kim W-Y, Gabriella R, Laus G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach J, Ciardiello F. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. Journal of Cellular Physiology, 216:698-707, 2008.
18. Kim W-Y*, Chang –DJ*, Henessy B, Kang HJ, Han SH, Kim YS, Mills G, Kim KW, Hong WK, Suh YG, Lee,HY, A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy , Cancer Prev Res 1: 577-587, 2008. (*, Co-First Authors).
19. Kim W-Y, Oh SH, Woo JK, Hong WK, Lee,HY . Targeting Heat Shock Protein 90 Overrides the Resistance of Lung Cancer Cells by Blocking Radiation-induced Stabilization of Hypoxia-inducible Factor 1α. Cancer Research,;69(4):1624-32 2009.
20. Kim W-Y, Lee HY. Brain angiogenesis in development and pathological processes: mechanism and therapeutic intervention in brain tumors. (review article, peer reviewed) FEBS J. 276(17):4653-64 2009.
21. Kim W-Y*, Jin Q*, Oh SH*, Kim E, Yang YY, Feng L, Behrens C, Prudkin L, Miller Y, Lee J, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Research. 69(18):7439-7448, 2009. (*, Co-First Authors).